Past Trial 15

Past Trial

A multicentre, randomised, double-blind, placebo-controlled, Phase 2 study comparing 3mg and 12mg of LY3202626 with placebo over 52 weeks in approximately 500 patients with mild Alzheimer’s disease dementia (NAVIGATE-AD).

Menu